In today’s briefing:
- Shanghai Microport Endovascular MedTech (688016.CH) – Not as Attractive as Lifetech
Shanghai Microport Endovascular MedTech (688016.CH) – Not as Attractive as Lifetech
- Although Endovastec has leading position in aortic products, the growth space of this field in China is relatively limited and is not enough to support the long-term development of Endovastec.
- The lack of revolutionary blockbuster product/candidate with global pricing power as well as the current weak international business layout are also the concerns.
- Our view is that Shanghai Microport Endovascular MedTech (688016 CH) (Endovastec) is a good company, but it is not as attractive as Lifetech Scientific (1302 HK) at the current stage.
Before it’s here, it’s on Smartkarma